

JosÃ© Luis Vizmanos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1156757/publications.pdf>

Version: 2024-02-01

58
papers

1,553
citations

331670

21
h-index

330143

37
g-index

60
all docs

60
docs citations

60
times ranked

2708
citing authors

#	ARTICLE	IF	CITATIONS
1	Zein-based nanocarriers for the oral delivery of insulin. In vivo evaluation in <i>Caenorhabditis elegans</i> . <i>Drug Delivery and Translational Research</i> , 2021, 11, 647-658.	5.8	8
2	A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms. <i>Cancers</i> , 2021, 13, 984.	3.7	17
3	In vivo testing of mucus-permeating nanoparticles for oral insulin delivery using <i>Caenorhabditis elegans</i> as a model under hyperglycemic conditions. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 989-1002.	12.0	15
4	Phenolic Compounds Reduce the Fat Content in <i>Caenorhabditis elegans</i> by Affecting Lipogenesis, Lipolysis, and Different Stress Responses. <i>Pharmaceuticals</i> , 2020, 13, 355.	3.8	23
5	Improvement of antioxidant activity of oregano (<i>Origanum vulgare</i> L.) with an oral pharmaceutical form. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110424.	5.6	17
6	A combination of borage seed oil and quercetin reduces fat accumulation and improves insulin sensitivity in obese rats. <i>Food and Function</i> , 2020, 11, 4512-4524.	4.6	7
7	Low doses of cocoa extract supplementation ameliorate diet-induced obesity and insulin resistance in rats. <i>Food and Function</i> , 2019, 10, 4811-4822.	4.6	15
8	Analysis of genes encoding epigenetic regulators in myeloproliferative neoplasms: Coexistence of a novel SETBP1 mutation in a patient with a p.V617F JAK2 positive myelofibrosis. <i>Molecular and Clinical Oncology</i> , 2019, 10, 639-643.	1.0	2
9	Broccoli extract improves high fat diet-induced obesity, hepatic steatosis and glucose intolerance in Wistar rats. <i>Journal of Functional Foods</i> , 2019, 59, 319-328.	3.4	19
10	A Simple and a Reliable Method to Quantify Antioxidant Activity In Vivo. <i>Antioxidants</i> , 2019, 8, 142.	5.1	59
11	Phenolic Compounds Inhibit 3T3-L1 Adipogenesis Depending on the Stage of Differentiation and Their Binding Affinity to PPAR γ . <i>Molecules</i> , 2019, 24, 1045.	3.8	61
12	Dihomo-gamma-linolenic acid induces fat loss in <i>C. elegans</i> in an omega-3-independent manner by promoting peroxisomal fatty acid β -oxidation. <i>Food and Function</i> , 2018, 9, 1621-1637.	4.6	18
13	Cyclodextrin-grafted poly(anhydride) nanoparticles for oral glibenclamide administration. In vivo evaluation using <i>C. elegans</i> . <i>International Journal of Pharmaceutics</i> , 2018, 547, 97-105.	5.2	20
14	<i>Borago officinalis</i> seed oil (BSO), a natural source of omega-6 fatty acids, attenuates fat accumulation by activating peroxisomal beta-oxidation both in <i>C. elegans</i> and in diet-induced obese rats. <i>Food and Function</i> , 2018, 9, 4340-4351.	4.6	20
15	Effects of Sample Size and Full Sibs on Genetic Diversity Characterization: A Case Study of Three Syntopic Iberian Pond-Breeding Amphibians. <i>Journal of Heredity</i> , 2017, 108, 535-543.	2.4	33
16	p.Y317H is a new <i>JAK2</i> gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with <i>CALR</i> mutation. <i>Haematologica</i> , 2017, 102, e328-e331.	3.5	6
17	Reliable effective number of breeders/adult census size ratios in seasonal breeding species: Opportunity for integrative demographic inferences based on capture-recapture data and multilocus genotypes. <i>Ecology and Evolution</i> , 2017, 7, 10301-10314.	1.9	14
18	Constitutional genetic association with <i>CALR</i> mutations?. <i>Leukemia</i> , 2015, 29, 2410-2411.	7.2	1

#	ARTICLE	IF	CITATIONS
19	Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling. <i>Leukemia</i> , 2014, 28, 2106-2109.	7.2	20
20	A simple approach for classifying new mutations as somatic or germinal in DNA samples lacking paired tissue. <i>BioTechniques</i> , 2014, 56, 327-9.	1.8	1
21	Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions. <i>Bioinformatics</i> , 2013, 29, 2539-2546.	4.1	87
22	CBL RING finger deletions are common in core-binding factor acute myeloid leukemias. <i>Leukemia and Lymphoma</i> , 2013, 54, 428-431.	1.3	6
23	A new <i>KRT16</i> mutation associated with a phenotype of pachyonychia congenita. <i>Experimental Dermatology</i> , 2013, 22, 838-839.	2.9	3
24	Genomic Hallmarks of Genes Involved in Chromosomal Translocations in Hematological Cancer. <i>PLoS Computational Biology</i> , 2012, 8, e1002797.	3.2	27
25	CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2. <i>Haematologica</i> , 2012, 97, 1234-1241.	3.5	19
26	Transforming and Tumorigenic Activity of JAK2 by Fusion to BCR: Molecular Mechanisms of Action of a Novel BCR-JAK2 Tyrosine-Kinase. <i>PLoS ONE</i> , 2012, 7, e32451.	2.5	27
27	A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1230-1233.	1.3	8
28	LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation. <i>Leukemia Research</i> , 2011, 35, 1537-1539.	0.8	18
29	LIF, a Novel STAT5-Regulated Gene, Is Aberrantly Expressed in Myeloproliferative Neoplasms. <i>Genes and Cancer</i> , 2011, 2, 593-596.	1.9	8
30	A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes. <i>Cancer Genetics and Cytogenetics</i> , 2010, 199, 1-8.	1.0	10
31	Quantification of <i>PDGFRA</i> alternative transcripts improves the screening for <i>PDGFRA</i> fusions by reverse transcriptase-polymerase chain reaction. <i>Leukemia and Lymphoma</i> , 2010, 51, 1720-1726.	1.3	0
32	Signatures of Selection in Fusion Transcripts Resulting From Chromosomal Translocations in Human Cancer. <i>PLoS ONE</i> , 2009, 4, e4805.	2.5	19
33	Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs. <i>Leukemia Research</i> , 2008, 32, 1485-1487.	0.8	3
34	Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2008, 32, 1638-1640.	0.8	16
35	TICdb: a collection of gene-mapped translocation breakpoints in cancer. <i>BMC Genomics</i> , 2007, 8, 33.	2.8	74
36	Multiplex PCR Assay for the Identification and Differentiation of all <i>Brucella</i> Species and the Vaccine Strains <i>Brucella abortus</i> S19 and RB51 and <i>Brucella melitensis</i> Rev1. <i>Clinical Chemistry</i> , 2006, 52, 779-781.	3.2	149

#	ARTICLE	IF	CITATIONS
37	JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. <i>Leukemia</i> , 2006, 20, 534-535.	7.2	41
38	Chromosome translocations in cancer: computational evidence for the random generation of double-strand breaks. <i>Trends in Genetics</i> , 2006, 22, 193-196.	6.7	15
39	Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. <i>Leukemia</i> , 2005, 19, 245-252.	7.2	69
40	NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2. <i>Cancer Genetics and Cytogenetics</i> , 2005, 157, 151-156.	1.0	7
41	A Gain of Function Mutation in JAK2 Is Frequently Found in Patients with AML-M2 and Normal Karyotype.. <i>Blood</i> , 2005, 106, 2366-2366.	1.4	40
42	NIN, a Gene Encoding a CEP110-Like Centrosomal Protein, Is Fused to PDGFRB in a Patient with a t(5;14)(q33;q24) and an Imatinib-Responsive Myeloproliferative Disorder 1. <i>Cancer Research</i> , 2004, 64, 2673-2676.	0.9	67
43	Cryptic ins(2;11) with clonal evolution showing amplification of 11q23-q25 either on hsr(11) or on dmin, in a patient with AML-M2. <i>Leukemia</i> , 2004, 18, 2041-2044.	7.2	6
44	Remission of acute monocytic leukemia, secondary to treatment with epipodophyllotoxins, in a patient with t(8;16)(p11;p13) and MYST3-CREBBP fusion. <i>Cancer Genetics and Cytogenetics</i> , 2004, 152, 177-178.	1.0	1
45	Cytogenetic profile of myelodysplastic syndromes with complex karyotypes: an analysis using spectral karyotyping. <i>Cancer Genetics and Cytogenetics</i> , 2004, 153, 39-47.	1.0	24
46	Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements. <i>Genes Chromosomes and Cancer</i> , 2004, 40, 179-189.	2.8	46
47	Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases. <i>The Hematology Journal</i> , 2004, 5, 534-537.	1.4	49
48	t(10;16)(q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2003, 36, 402-405.	2.8	28
49	TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia. <i>Molecular Carcinogenesis</i> , 2003, 38, 201-208.	2.7	58
50	Novel translocations that disrupt the platelet-derived growth factor receptor β^2 (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. <i>British Journal of Haematology</i> , 2003, 120, 251-256.	2.5	87
51	Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients. <i>Oncogene</i> , 2003, 22, 1070-1072.	5.9	73
52	Peptide Inhibitors of Hepatitis C Virus NS3 Protease. <i>Antiviral Chemistry and Chemotherapy</i> , 2003, 14, 225-233.	0.6	6
53	NUP98 is fused to adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15). <i>Cancer Research</i> , 2003, 63, 3079-83.	0.9	31
54	Exon Concatenation to Increase the Efficiency of Mutation Screening by DGGE. <i>BioTechniques</i> , 2002, 32, 1064-1070.	1.8	5

#	ARTICLE	IF	CITATIONS
55	A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 11-19.	2.8	28
56	Two new molecular PML-RARalpha variants: implications for the molecular diagnosis of APL. <i>Haematologica</i> , 2002, 87, ELT37.	3.5	5
57	Degree and distribution of variability in the 5' untranslated, E1, E2/NS1 and NS5 regions of the hepatitis C virus (HCV). <i>Journal of Viral Hepatitis</i> , 1998, 5, 227-240.	2.0	16
58	The GCGGAA gene-regulatory motif of herpes simplex virus type-1 is also found in hepatitis C virus. <i>Gene</i> , 1995, 154, 131-132.	2.2	1